NCPC(SH:600812)2023-04-21 16:00Financial Performance - In 2022, the company reported a net loss of approximately ¥678.78 million, with a net loss attributable to shareholders of approximately ¥689.23 million[5]. - The company's parent entity achieved a net profit of approximately ¥28.12 million for the year[5]. - The undistributed profits at the end of 2022 amounted to approximately ¥739.78 million after accounting for the legal surplus reserve and previous year dividends[5]. - The company plans not to distribute profits for 2022, nor to increase capital reserves through stock conversion, to ensure sustainable development and risk resilience[5]. - The company achieved an operating revenue of CNY 10.50 billion in 2022, a year-on-year increase of 1.11% compared to CNY 10.38 billion in 2021[22]. - The net profit attributable to shareholders was CNY -689.23 million, a significant decrease of 3,780.33% from CNY 18.73 million in 2021[22]. - The company recorded a net cash flow from operating activities of CNY 1.00 billion, down 4.37% from CNY 1.05 billion in 2021[22]. - The weighted average return on equity decreased to -12.11% in 2022, down 12.42 percentage points from 0.31% in 2021[23]. - The company reported a total asset value of CNY 21.22 billion at the end of 2022, a decrease of 14.88% from CNY 24.93 billion at the end of 2021[22]. - The total profit decreased to -565 million RMB, a decline of 518.87% compared to the previous year[60]. Operational Challenges - The company faced significant challenges, including a provision for bad debts of CNY 727.39 million related to relocation and suspension losses, impacting the net profit[32]. - The company generated CNY 2.54 billion in revenue in Q1 2022, with a net profit of CNY 13.68 million, but reported a net loss of CNY 727.17 million in Q4 2022[27]. - The company has not engaged in non-operational fund occupation by controlling shareholders or related parties[7]. - There were no significant risks that materially affected the company's operations during the reporting period[9]. Research and Development - The company increased its R&D investment to 609 million yuan, achieving an investment intensity of 5.80%[34]. - The company applied for 52 patents in 2022, including 33 invention patents, and was granted 45 patents[34]. - The company established three provincial-level research platforms, enhancing its R&D capabilities[34]. - The company is actively pursuing strategic collaborations with key universities and research institutions to accelerate product development[34]. - The company has established a comprehensive R&D system, including 4 national innovation platforms and 11 provincial innovation platforms, enhancing its research capabilities[105]. - The company is currently developing several new products, including a new anticoagulant drug in clinical trial phase and a rabies virus antibody product that received its registration certificate in January 2022[106]. Market Expansion and Sales Strategy - The company successfully expanded its international market, achieving overseas sales of CNY 1.59 billion in 2022[33]. - The company implemented a new marketing strategy, including an internet marketing plan, to enhance its sales capabilities and stabilize its revenue base[33]. - The company is exploring online drug sales, gradually increasing the number of varieties and expanding specialized treatment categories[46]. - The company is focusing on developing new treatment areas such as cardiovascular, anti-tumor, kidney disease, and diabetes products[59]. - The company plans to continue expanding its market presence and product diversity in response to changing market conditions[66]. - The company is considering strategic acquisitions to bolster its product portfolio, with a budget of $100 million allocated for potential deals[94]. Environmental Responsibility - The company invested 24,000,000 CNY in environmental protection during the reporting period[186]. - The company has established a comprehensive environmental management system and has passed the ISO14001 certification[187]. - The company operates 14 key pollutant discharge units across 19 production sites, demonstrating its commitment to environmental responsibility[188]. - The company has implemented a performance evaluation system for senior management, linking compensation to company performance[181]. - The company’s wastewater discharge is continuously monitored and complies with the standards set by the downstream sewage treatment plant[189]. Corporate Governance - The company has maintained a policy of independence from its controlling shareholders, ensuring no significant impact from related party transactions[148]. - The company has established specialized committees under the board, including an audit committee and a strategic committee, to enhance governance[165]. - The company has a structured process for nominating and compensating its directors and senior management, ensuring transparency and accountability[159]. - The company has actively participated in board and shareholder meetings, with directors attending all required sessions[163]. - The company has undergone changes in its board of directors, with several members being elected or resigning due to age or work reasons[160]. Future Outlook - The company is focused on cost reduction, efficiency improvement, and risk control as part of its operational strategy for 2023[135]. - The company plans to enhance its governance structure and improve operational efficiency in 2023[136]. - The company aims to achieve operating revenue of 11 billion yuan and a total profit of 120 million yuan in 2023[135]. - The company provided guidance for the next quarter, expecting revenue to be between $1.6 billion and $1.7 billion, which reflects a growth rate of approximately 10%[94]. - Future outlook remains positive, with expectations of improved financial performance driven by strategic initiatives[153].